[人原发性上皮性卵巢癌中c-erbB2基因扩增及其临床意义]

[c-erbB2 gene amplification in human primary epithelial ovarian cancer and its clinical significance].

作者信息

Yang H, Zhang G, Xu K

机构信息

Shanghai Cancer Hospital, Shanghai Medical University.

出版信息

Zhonghua Zhong Liu Za Zhi. 1998 Sep;20(5):367-70.

PMID:10921034

Abstract

OBJECTIVE

To study c-erbB2 gene amplification in human primary epithelial ovarian cancer and its clinical significance.

METHODS

One hundred forty nine samples of primary epithelial ovarian tumors, including 34 beign tumors, 7 borderline tumors and 108 carcinoma, were studied for c-erbB2 gene amplification by Southern blot analysis.

RESULTS

c-erbB2 gene amplification was detected in 35 (32.4%) of the 108 cases with primaey epithelial ovarian carcinoma, while all cases with beign tumors and borderline lesions were negative (P < 0.001). There was a strong correlation between c-erbB2 gene amplification and FIGO stage of human ovarian carcinoma (P = 0.026), degree of cell differentiation (P = 0.011) and the size of residual tumor (P < 0.001). Univariate and multivariate analysis showed that c-erbB2 gene amplification was an independent prognostic factor. The average 3-year survival rate was 28.4% in patients with gene amplification and 57.7% in patients without gene amplification(P = 0.016).

CONCLUSION

c-erbB2 gene amplification occurs almost in 1/3 of the patients with ovarian carcinoma examined. Ovarian carcinoma with c-erbB2 gene amplification is highly malignant and associated with poor prognosis.

摘要

目的

研究人原发性上皮性卵巢癌中c-erbB2基因扩增及其临床意义。

方法

采用Southern印迹分析法对149例原发性上皮性卵巢肿瘤样本进行研究，其中包括34例良性肿瘤、7例交界性肿瘤和108例癌。

结果

108例原发性上皮性卵巢癌患者中，35例（32.4%）检测到c-erbB2基因扩增，而所有良性肿瘤和交界性病变患者均为阴性（P < 0.001）。c-erbB2基因扩增与人卵巢癌的FIGO分期（P = 0.026）、细胞分化程度（P = 0.011）及残留肿瘤大小（P < 0.001）之间存在密切相关性。单因素和多因素分析表明，c-erbB2基因扩增是一个独立的预后因素。基因扩增患者的平均3年生存率为28.4%，无基因扩增患者为57.7%（P = 0.016）。